Skip to main content
OpenTrials
Completed

NCT Number: NCT00060476

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

50 year–75 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

About this study

The duration of treatment is 6 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Regular PSA testing and study biopsies required.

Treatment and study plan

Rofecoxib

Drug

Other names: MK0966

Comparator: Placebo (Unspecified)

Drug

Primary outcomes

  1. Time to prostate cancer

    Time frame: Duration of Treatment

Secondary outcomes

  1. Time to aggressive prostate cancer

    Time frame: Duration of Treatment

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)

Important dates

Study start
2003
Primary completion
2004
Study completion
2004
First posted
May 7, 2003
Registry last updated
May 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.